Recent Updates
Recently added Catalysts
SRPT Negative Sentiment Score: 25/100

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT

Key Takeaway: Sarepta Therapeutics, Inc. is facing a class action securities lawsuit led by Levi & Korsinsky, LLP, which seeks to recover losses for investors affected by alleged securities fraud. The complaint asserts that the company misled investors regarding the safety of its gene therapy, ELEVIDYS, and the efficacy of its clinical trial protocols. It also indicates that serious safety concerns could halt trial activities and regulatory approvals. Investors who believe they have suffered losses have until August 25, 2025, to participate in the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Sarepta for alleged securities fraud.
  • Claims that ELEVIDYS gene therapy poses significant safety risks to patients.
  • Allegations that trial protocols failed to detect severe side effects.
  • Potential regulatory scrutiny and halted recruitment due to adverse events.

Full Press Release Details

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:
SRPT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
WHAT'S NEXT? If you suffered a loss in Sarepta during the relevant time frame, you have until August 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit against Sarepta about?

The lawsuit involves Sarepta investors claiming losses due to alleged securities fraud between June 22, 2023, and June 24, 2025.

What are the main allegations in the Sarepta lawsuit?

The lawsuit alleges false statements regarding ELEVIDYS's safety risks and trial failures.

How can Sarepta investors participate in the lawsuit?

Investors can request lead plaintiff status by August 25, 2025, or join without serving as lead.

Will there be any costs for participating in the lawsuit?

Class members may receive compensation without any out-of-pocket costs or fees.

Why choose Levi & Korsinsky for representation?

Levi & Korsinsky has a strong track record in securities litigation, recovering significant amounts for shareholders.

Last updated: Jul 31, 2025